Stanford University

Showing 961-970 of 2,473 Results

• 

  Andrei Iagaru

  Professor of Radiology (Nuclear Medicine)
  

  Current Research and Scholarly InterestsCurrent research projects include:
  1) PET/MRI and PET/CT for Early Cancer Detection
  2) Targeted Radionuclide Therapy
  3) Clinical Translation of Novel PET Radiopharmaceuticals;

  • Contact Info

  • Web page:

    http://nuclearmedicine.stanford.edu/people/aiagaru.html
• 

  Albina Ibrayeva

  Director of Scientific Portfolio, Initiative in Brain Resilience
  
• 

  Thomas Icard

  Clarence Irving Lewis Professor of Philosophy and Professor, by courtesy, of Computer Science
  

  • Contact Info

  • Web page:

    http://web.stanford.edu/people/icard
• Jennifer Ignacio

  IRB Manager, Vice Provost and Dean of Research - Research Compliance
  
• 

  Yusuke Iguchi

  Affiliate, Applied Physics
  
• David Chinazaekpere Ifeanyichuk Ihim

  Affiliate, Institute for Human-Centered Artificial Intelligence (HAI)
  
• 

  Matthias Ihme

  Professor of Mechanical Engineering, of Photon Science and, by courtesy, of Energy Science and Engineering
  

  BioLarge-eddy simulation and modeling of turbulent reacting flows, non-premixed flame, aeroacoustics and combustion generated noise, turbulence and fluid dynamics, numerical methods and high-order schemes.
• 

  Gentaro Ikeda

  Instructor, Medicine - Cardiovascular Medicine
  

  BioDr. Ikeda is a physician-scientist who develops innovative diagnostic and therapeutic modalities for patients with cardiovascular disease. Based on his clinical experience as a cardiologist, he has become aware of major clinical shortcomings, specifically in the current pharmaceutical therapies for myocardial infarction (MI) and chronic heart failure (HF). Some evidence-based drug therapies, including β-blockers, ivabradine, and renin-angiotensin-aldosterone antagonists are difficult to apply to critical patients due to adverse side effects. Drugs that have shown efficacy in basic animal experiments have failed to show significant benefits in clinical trials. To address these problems, he moved to academia to conduct translational research. During his graduate training in the Egashira Lab, he focused on drug delivery systems (DDS) that target mitochondria in animal models of MI. He obtained advanced skills in molecular biology, mitochondrial bioenergetics, and animal surgery. He realized the importance of translational research and the great potential of DDS to overcome many clinical problems. He developed nanoparticle-mediated DDS containing cyclosporine for the treatment of patients with MI. He published a first-author paper and received academic awards for his novel science. Since becoming a postdoctoral fellow in the Yang Lab, he has continued to build upon his previous training in translational research. He is currently developing an innovative therapy, namely, extracellular vesicles-mediated mitochondrial transfer for mitochondria-related diseases such as heart failure and mitochondrial disease.
• Guido Imbens

  Applied Econometrics Professor, Professor of Economics and Senior Fellow at the Stanford Institute for Economic Policy Research
  
• 

  Daniel Imler

  Clinical Associate Professor, Emergency Medicine
  Clinical Associate Professor, Pediatrics
  

  Current Research and Scholarly InterestsI am interested in understanding the impact of smart, agile clinical pathways to drive behavior change among providers.